vida: extract claims from 2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos

- Source: inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
- Domain: health
- Claims: 2, Entities: 2
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/mdma-assisted-therapy-functional-unblinding-invalidates-self-reported-outcomes-despite-phase3-efficacy.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: FDA's 10-1 advisory committee vote against MDMA-AT approval despite positive Phase 3 efficacy establishes that pronounced psychoactive effects create structural methodological failure
+confidence: proven
+source: FDA Complete Response Letter to Lykos Therapeutics, August 9, 2024; FDA PDAC Advisory Committee vote June 4, 2024
+created: 2026-05-10
+title: MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
+agent: vida
+sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
+scope: structural
+sourcer: FDA / Psychiatric Times / STAT News
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
+---
+
+# MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
+
+The FDA rejected Lykos Therapeutics' MDMA-assisted therapy for PTSD despite statistically significant Phase 3 efficacy (MAPP1 and MAPP2 trials showed CAPS-5 score reductions). The rejection centered on functional unblinding: MDMA's pronounced empathogenic and euphoric effects mean participants reliably know whether they received active drug or placebo. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity—essentially unanimous agreement that MDMA trials cannot use inert placebo controls. This is a STRUCTURAL problem, not fixable through protocol modifications. The FDA explicitly required an additional Phase 3 study, indicating the existing evidence base was methodologically invalid despite clinical benefit. The contrast with psilocybin is instructive: Compass Pathways used 1mg as active placebo comparator (visually and experientially distinct from 25mg therapeutic dose) rather than inert placebo, and their Phase 3 trials passed FDA scrutiny. The divergence reveals that regulatory success depends not just on efficacy but on trial methodology that preserves outcome validity. For psychiatry trials relying on self-reported outcomes, functional unblinding creates systematic bias that invalidates results regardless of true clinical benefit.

domains/health/psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The MDMA rejection versus psilocybin approval pathway divergence establishes that trial design must account for psychoactive intensity—inert placebo fails for pronounced effects
+confidence: likely
+source: FDA MDMA CRL August 2024; Compass Pathways Phase 3 design using 1mg active comparator
+created: 2026-05-10
+title: Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
+agent: vida
+sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
+scope: structural
+sourcer: FDA / Psychiatric Times / STAT News
+---
+
+# Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
+
+The FDA's rejection of MDMA-assisted therapy while psilocybin trials advance reveals a critical design constraint: the intensity of psychoactive effects determines viable trial methodology. MDMA produces pronounced empathogenic and euphoric effects that make functional unblinding inevitable with inert placebo—participants know they received the drug. The FDA advisory committee's 10-1 vote established this as disqualifying for self-reported psychiatric outcomes. In contrast, Compass Pathways' psilocybin trials used 1mg as active comparator (producing some perceptual effects) versus 25mg therapeutic dose, addressing the blinding concern through dose differentiation rather than inert placebo. This design choice allowed psilocybin trials to pass FDA scrutiny that MDMA trials failed. The implication generalizes: any highly psychoactive compound faces the same structural challenge. Future trials must either use active comparators that preserve some degree of blinding, or shift to objective endpoints (biomarkers, clinician-rated outcomes, behavioral measures) that are less vulnerable to expectancy bias. The functional unblinding problem is not solvable through protocol refinements—it requires fundamental redesign of trial architecture based on the compound's psychoactive profile.

entities/health/lykos-therapeutics.md

@@ -0,0 +1,56 @@
+# Lykos Therapeutics
+
+**Type:** Pharmaceutical company (formerly MAPS Public Benefit Corporation)
+**Focus:** MDMA-assisted therapy for PTSD
+**Status:** Post-CRL restructuring (75% staff reduction as of August 2024)
+
+## Overview
+
+Lykos Therapeutics (formerly the public benefit corporation arm of MAPS - Multidisciplinary Association for Psychedelic Studies) developed MDMA-assisted therapy for post-traumatic stress disorder. The company conducted pivotal Phase 3 trials (MAPP1 and MAPP2) that showed statistically significant reductions in PTSD symptoms measured by CAPS-5 scores.
+
+## Regulatory History
+
+### FDA Complete Response Letter (August 9, 2024)
+
+The FDA rejected Lykos's New Drug Application for MDMA-assisted therapy, citing:
+
+1. **Functional unblinding:** MDMA's pronounced psychoactive effects (empathogenic, euphoric) meant participants could reliably identify whether they received active drug or placebo, biasing self-reported outcomes. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity.
+
+2. **Data reliability concerns:** Systematic documentation issues for abuse-related adverse events and site oversight problems at clinical trial sites.
+
+3. **Cardiovascular risk:** Acute cardiovascular effects (heart rate and blood pressure elevation) raised safety concerns for broader population use.
+
+4. **Insufficient duration data:** Inadequate data to guide clinicians on duration of MDMA's therapeutic effects.
+
+The FDA required an additional Phase 3 study. No resubmission timeline has been announced as of May 2026.
+
+### FDA Advisory Committee Review (June 4, 2024)
+
+- **Benefit-risk vote:** 8-1 adverse
+- **Functional unblinding vote:** 10-1 adverse (essentially unanimous that blinding failure invalidated trial methodology)
+
+## Organizational Impact
+
+- Laid off approximately 75% of staff following the Complete Response Letter
+- Separated operations from MAPS PBC (nonprofit parent organization)
+- Meeting with FDA to request reconsideration and discuss resubmission pathway
+
+## Clinical Trial Program
+
+**Phase 3 Trials:**
+- MAPP1 and MAPP2 showed statistically significant PTSD symptom reductions
+- Used inert placebo comparator (later identified as methodological flaw)
+- Efficacy demonstrated but methodology deemed invalid by FDA
+
+## Timeline
+
+- **2024-06-04** — FDA Psychopharmacologic Drugs Advisory Committee votes 10-1 against approval based on functional unblinding concerns
+- **2024-08-09** — FDA issues Complete Response Letter rejecting NDA, requiring additional Phase 3 study
+- **2024-08** — Lykos lays off ~75% of staff following CRL
+- **2025-09-04** — Complete Response Letter made public
+
+## Sources
+
+- FDA Complete Response Letter, August 9, 2024
+- Psychiatric Times coverage, September 2025
+- STAT News reporting, October 2025

entities/health/maps-pbc.md

@@ -0,0 +1,23 @@
+# MAPS Public Benefit Corporation
+
+**Type:** Nonprofit public benefit corporation
+**Parent:** Multidisciplinary Association for Psychedelic Studies (MAPS)
+**Focus:** Psychedelic-assisted therapy development
+**Status:** Separated from Lykos Therapeutics operations (2024)
+
+## Overview
+
+MAPS Public Benefit Corporation was the nonprofit pharmaceutical development arm of MAPS (Multidisciplinary Association for Psychedelic Studies), a 40+ year organization pioneering psychedelic therapy research. MAPS PBC created Lykos Therapeutics to advance MDMA-assisted therapy through FDA approval.
+
+## Organizational Structure
+
+MAPS PBC operated as the parent organization to Lykos Therapeutics, maintaining nonprofit status while conducting pharmaceutical development. Following the FDA Complete Response Letter in August 2024, MAPS PBC and Lykos separated operations.
+
+## Timeline
+
+- **2024-08** — Separated operations from Lykos Therapeutics following FDA Complete Response Letter
+
+## Sources
+
+- Psychiatric Times, September 2025
+- STAT News, October 2025

inbox/archive/health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md

@@ -7,10 +7,13 @@ date: 2024-08-09
 domain: health
 secondary_domains: []
 format: regulatory-document
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: medium
 tags: [MDMA, PTSD, FDA, complete-response-letter, Lykos-Therapeutics, MAPS, clinical-trial, functional-unblinding, psychedelic-therapy]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content